title: Cost-effectiveness of the low molecular weight heparin reviparin sodium in thromboprophylaxis.
abstract: Use of low molecular weight heparins (LMWHs) is now generally accepted as an ideal method of prophylaxis against postoperative venous thromboembolism. However, the long-term effects on the development of postthrombotic deep vein insufficiency are not known. Every patient developing such complications consumes a vast amount of resources, in terms of both direct and indirect costs. Our cost-effective analysis indicates that LMWH (reviparin sodium) is most cost-saving for both direct and indirect costs, particularly in high risk patients undergoing major surgery.
authors.affiliation: Thrombosis Research Institute, London, UK.
authors.forename: V V
authors.initials: VV
authors.lastname: Kakkar
mesh_terms: D000925:Anticoagulants / Q000191:economics* / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D006495:Heparin, Low-Molecular-Weight / Q000191:economics* / Q000627:therapeutic use; D006801:Humans; D011183:Postoperative Complications / Q000191:economics / Q000517:prevention & control; D013927:Thrombosis / Q000191:economics / Q000517:prevention & control*; D014859:Warfarin / Q000191:economics / Q000627:therapeutic use
chemical_list: D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight; D014859:Warfarin; C094240:reviparin